Genistein and daidzein act on a panel of genes implicated in cell cycle and angiogenesis by Polymerase Chain Reaction arrays in human prostate cancer cell lines

Cancer Epidemiology

Volumn 34, Issue 2, 2010, Pages 200-206

  Rabiau, Nadège ^a,b,c   Kossaï, Myriam ^a,b   Braud, Martin ^a,b   Chalabi, Nasséra ^a,b   Satih, Samir ^a,b   Bignon, Yves Jean ^a,b,d   Bernard Gallon, Dominique J ^a,b  

^a CENTRE JEAN PERRIN   (France)

^b CNRH   (France)

^c Biopôle Clermont Limagne ^*  (France)

^d UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Angiogenesis arrays; Cell cycle arrays; Daidzein; Genistein; Prostate cancer cell lines; SYBR green

Indexed keywords

CYCLIN DEPENDENT KINASE; DAIDZEIN; EPIDERMAL GROWTH FACTOR; GENISTEIN; PHYTOESTROGEN; SOMATOMEDIN; ANTINEOPLASTIC AGENT; ISOFLAVONE DERIVATIVE;

ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CARCINOGENESIS; CELL CYCLE ARREST; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; ENVIRONMENTAL FACTOR; FLOW CYTOMETRY; GENE EXPRESSION; HEREDITY; HUMAN; HUMAN CELL; INCUBATION TIME; NUTRITIONAL STATUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; SOYBEAN; CELL CYCLE; DRUG EFFECTS; GENETICS; MALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PROSTATE TUMOR; TUMOR CELL LINE; VASCULARIZATION;

ANTICARCINOGENIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; DOWN-REGULATION; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION; GENISTEIN; HUMANS; ISOFLAVONES; MALE; NEOVASCULARIZATION, PATHOLOGIC; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; SOMATOMEDINS;

EID: 77950371401     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2009.12.018     Document Type: Article

References (49)

1. Simard J., Dumont M., Labuda D., Sinnett D., Meloche C., El-Alfy M., et al. Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocr Relat Cancer 10 (2003) 225-259
2. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
3. Colonna M., Danzon A., Delafosse P., Mitton N., Bara S., Bouvier A.M., et al. Cancer prevalence in France: time trend, situation in 2002 and extrapolation to 2012. Eur J Cancer 44 (2008) 115-122
4. Hill C., and Doyon F. The frequency of cancer in France in year 2000, and trends since 1950. Bull Cancer 92 (2005) 7-11
5. Hsing A.W., Tsao L., and Devesa S.S. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 85 (2000) 60-67
6. Cook L.S., Goldoft M., Schwartz S.M., and Weiss N.S. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol 161 (1999) 152-155
7. Shimizu H., Ross R.K., Bernstein L., Yatani R., Henderson B.E., and Mack T.M. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 63 (1991) 963-966
8. Sim H.G., and Cheng C.W. Changing demography of prostate cancer in Asia. Eur J Cancer 41 (2005) 834-845
9. Magee P.J., and Rowland I.R. Phyto-oestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br J Nutr 91 (2004) 513-531
10. Messina M.J. Emerging evidence on the role of soy in reducing prostate cancer risk. Nutr Rev 61 (2003) 117-131
11. Messina M., Kucuk O., and Lampe J.W. An overview of the health effects of isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels. J AOAC Int 89 (2006) 1121-1134
12. Nakamura Y., Tsuji S., and Tonogai Y. Determination of the levels of isoflavonoids in soybeans and soy-derived foods and estimation of isoflavonoids in the Japanese daily intake. J AOAC Int 83 (2000) 635-650
13. Steiner C., Arnould S., Scalbert A., and Manach C. Isoflavones and the prevention of breast and prostate cancer: new perspectives opened by nutrigenomics. Br J Nutr 99 E Suppl. 1 (2008) ES78-ES108
14. Pollard M., and Suckow M.A. Dietary prevention of hormone refractory prostate cancer in Lobund-Wistar rats: a review of studies in a relevant animal model. Comp Med 56 (2006) 461-467
15. Wang J., Eltoum I.E., and Lamartiniere C.A. Dietary genistein suppresses chemically induced prostate cancer in Lobund-Wistar rats. Cancer Lett 186 (2002) 11-18
16. Hedlund T.E., Johannes W.U., and Miller G.J. Soy isoflavonoid equol modulates the growth of benign and malignant prostatic epithelial cells in vitro. Prostate 54 (2003) 68-78
17. Fang M.Z., Chen D., Sun Y., Jin Z., Christman J.K., and Yang C.S. Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin Cancer Res 11 (2005) 7033-7041
18. Li Y., Ahmed F., Ali S., Philip P.A., Kucuk O., and Sarkar F.H. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 65 (2005) 6934-6942
19. Barnes S., and Peterson T.G. Biochemical targets of the isoflavone genistein in tumor cell lines. Proc Soc Exp Biol Med 208 (1995) 103-108
20. Satih S., Rabiau N., Bignon Y.J., and Bernard-Gallon D.J. Soy phytoestrogens and breast cancer chemoprevention: molecular mechanisms. Curr Nutr Food Sci 4 (2008) 259-264
21. Fotsis T., Pepper M., Adlercreutz H., Fleischmann G., Hase T., Montesano R., et al. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA 90 (1993) 2690-2694
22. Fotsis T., Pepper M., Adlercreutz H., Hase T., Montesano R., and Schweigerer L. Genistein, a dietary ingested isoflavonoid, inhibits cell proliferation and in vitro angiogenesis. J Nutr 125 (1995) 790S-797S
23. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 66 (1975) 188-193
24. Favy D.A., Lafarge S., Rio P., Vissac C., Bignon Y.J., and Bernard-Gallon D. Real-time PCR quantification of full-length and exon 11 spliced BRCA1 transcripts in human breast cancer cell lines. Biochem Biophys Res Commun 274 (2000) 73-78
25. Oki T., Sowa Y., Hirose T., Takagaki N., Horinaka M., Nakanishi R., et al. Genistein induces Gadd45 gene and G2/M cell cycle arrest in the DU145 human prostate cancer cell line. FEBS Lett 577 (2004) 55-59
26. Shenouda N.S., Zhou C., Browning J.D., Ansell P.J., Sakla M.S., Lubahn D.B., et al. Phytoestrogens in common herbs regulate prostate cancer cell growth in vitro. Nutr Cancer 49 (2004) 200-208
27. Kobayashi T., Nakata T., and Kuzumaki T. Effect of flavonoids on cell cycle progression in prostate cancer cells. Cancer Lett 176 (2002) 17-23
28. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
29. Gartel A.L., and Tyner A.L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1 (2002) 639-649
30. Handayani R., Rice L., Cui Y., Medrano T.A., Samedi V.G., Baker H.V., et al. Soy isoflavones alter expression of genes associated with cancer progression, including interleukin-8, in androgen-independent PC-3 human prostate cancer cells. J Nutr 136 (2006) 75-82
31. Karan D., Kelly D.L., Rizzino A., Lin M.F., and Batra S.K. Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis 23 (2002) 967-975
32. Ko L.J., Shieh S.Y., Chen X., Jayaraman L., Tamai K., Taya Y., et al. p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner. Mol Cell Biol 17 (1997) 7220-7229
33. Padmanabhan V., Callas P., Philips G., Trainer T.D., and Beatty B.G. DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer. J Clin Pathol 57 (2004) 1057-1062
34. Takisawa H., Mimura S., and Kubota Y. Eukaryotic DNA replication: from pre-replication complex to initiation complex. Curr Opin Cell Biol 12 (2000) 690-696
35. Berner A., Geitvik G., Karlsen F., Fossa S.D., Nesland J.M., and Borresen A.L. TP53 mutations in prostatic cancer. Analysis of pre- and post-treatment archival formalin-fixed tumour tissue. J Pathol 176 (1995) 299-308
36. Zheng L., Wang F., Qian C., Neumann R.M., Cheville J.C., Tindall D.J., et al. Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines. Hum Mutat 27 (2006) 1062-1063
37. Agarwal R. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol 60 (2000) 1051-1059
38. Aragon-Ching J.B., and Dahut W.L. The role of angiogenesis inhibitors in prostate cancer. Cancer J 14 (2008) 20-25
39. Li Y., and Sarkar F.H. Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein. Cancer Lett 186 (2002) 157-164
40. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262 (1987) 5592-5595
41. Wang J., Eltoum I.E., and Lamartiniere C.A. Genistein chemoprevention of prostate cancer in TRAMP mice. J Carcinog 6 (2007) 3
42. Gadgeel S.M., Ali S., Philip P.A., Wozniak A., and Sarkar F.H. Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines. Cancer 115 (2009) 2165-2176
43. Zhang J., and Hughes S. Role of the ephrin and Eph receptor tyrosine kinase families in angiogenesis and development of the cardiovascular system. J Pathol 208 (2006) 453-461
44. Buzza M., Dagher H., Wang Y.Y., Wilson D., Babon J.J., Cotton R.G., et al. Mutations in the COL4A4 gene in thin basement membrane disease. Kidney Int 63 (2003) 447-453
45. Lehrer S., Diamond E.J., Mamkine B., Stone N.N., and Stock R.G. Serum interleukin-8 is elevated in men with prostate cancer and bone metastases. Technol Cancer Res Treat 3 (2004) 411
46. Trojan L., Schaaf A., Steidler A., Haak M., Thalmann G., Knoll T., et al. Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines. Anticancer Res 25 (2005) 183-191
47. Engl T., Relja B., Blumenberg C., Muller I., Ringel E.M., Beecken W.D., et al. Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life Sci 78 (2006) 1784-1793
48. Lendeckel U., Arndt M., Frank K., Wex T., and Ansorge S. Role of alanyl aminopeptidase in growth and function of human T cells (review). Int J Mol Med 4 (1999) 17-27
49. Ishii K., Usui S., Sugimura Y., Yamamoto H., Yoshikawa K., and Hirano K. Inhibition of aminopeptidase N (AP-N) and urokinase-type plasminogen activator (uPA) by zinc suppresses the invasion activity in human urological cancer cells. Biol Pharm Bull 24 (2001) 226-230